Navigation Links
New muscular dystrophy treatment shows promise in early study led by Children's National
Date:9/17/2013

WASHINGTON, DC A preclinical study led by researchers at Children's National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug, VBP15, decreases inflammation and protects and strengthens muscle without the harsh side effects linked to current treatments with glucocorticoids such as prednisone.

Duchenne muscular dystrophy results in severe muscle degeneration and affects approximately 180,000 patients worldwide, mostly children. The current standard treatment uses glucocorticoids, but is limited due to serious side effects leading to fragile bones and suppression of both the immune system and growth.

"These findings, while preliminary, are very promising for advancing the treatment of this disease, which causes disability in so many children worldwide," said Eric P. Hoffman, PhD, director of the Center for Genetic Medicine Research at Children's National. "The study also suggests the potential for new strategies in very early treatment, which could further benefit patients."

The Children's National research team also observed that VBP15 inhibits the transcription factor NF-κB, a key cell-signaling molecule found in most cell types that plays a role in inflammation and tissue damage. The team previously found that NF-κB is active in dystrophin-deficient muscle years before the onset of symptoms, suggesting that very early treatment of Duchenne muscular dystrophy patients with VBP15 may prevent or delay the onset of some clinical symptoms.

"VBP15 has an additional property of addressing membrane defects in dystrophic muscle cells," remarked

Contact: Emily Hartman
ehartman@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Combined therapy could repair and prevent damage in Duchenne muscular dystrophy
2. New drug improves walking performance for Duchenne muscular dystrophy patients
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
5. Scientists discover needle in a haystack for muscular dystrophy patients
6. Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy
7. Stem-cell approach shows promise for Duchenne muscular dystrophy
8. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
9. Another muscular dystrophy mystery solved; MU scientists inch closer to a therapy for patients
10. Protein injection points to muscular dystrophy treatment
11. Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may be ... be more careful. In the wild, a plant whose seeds ... risk disaster. More than just an insurance policy against late ... dormancy has long-term advantages too: Plants whose seeds put ... more species, finds in a team of researchers working at ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... deafness. , As a leader in stem cell-based research on the ... got a step-by-step plan for making this dream a reality. ... anyone can do it, he's the guy to place your ... this?'" said Heller, PhD, associate professor of otolaryngology, whose accent ...
... all remember a time when we were paralyzed in the ... world, making the right choice can mean the difference between ... choose the thing that leads to a "reward," such as ... and understanding those changes has been the focus of Natural ...
... Your bird field guide may be out of date now ... frogmouth bird on a South Pacific island. , New ... per year is announced globally. David Steadman and Andrew Kratter, ... the surprising new discovery on a collecting expedition in the ...
Cached Biology News:Stem cell transplants explored at Stanford as a possible treatment for hearing loss 2Stem cell transplants explored at Stanford as a possible treatment for hearing loss 3Rewarding fat rats 2UF scientists discover new genus of frogmouth bird in Solomon Islands 2UF scientists discover new genus of frogmouth bird in Solomon Islands 3
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Class Group of AdvisorsSAN DIEGO, April 20 Trius ... Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, ... seventh members of the group of anti-infective thought leaders. ... Michigan State University and the Chief of ...
... at 100th Annual Meeting of the American Association for ... from Dendreon Corporation (Nasdaq: DNDN ) presented ... Cancer Treatment) or P-11 Phase 3 study suggesting that ... durable and can be maintained following boosting. The results ...
... have discovered a way to use an ancient life form ... in systems that may be surprisingly simple to build compared ... These tiny, single-celled marine life forms have existed for at ... of the life in the oceans, but they also have ...
Cached Biology Technology:Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 3Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 4Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 5Ancient diatoms lead to new technology for solar energy 2
... high throughput, water bath thermal cycler capable of ... This equates to 9,216 reactions per run when ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Proliferin (C-14)...
... Dideoxycytidine is a cytidine analog that has been ... Immunogen: Chemical / Small Molecule ... specificity of the ddC antiserum was determined by ... to moles of ddC analog at the 50% ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
Biology Products: